Aprea Therapeutics (NASDAQ:APRE) Stock Falls 3.5% – Here’s Why

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s share price dropped 3.5% during trading on Thursday. The company traded as low as $0.6750 and last traded at $0.7235. 772,588 shares were traded during trading, an increase of 347% from the average daily volume of 172,868 shares. The stock had previously closed at $0.75.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Wedbush reduced their target price on Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aprea Therapeutics presently has an average rating of “Hold” and an average price target of $3.07.

Aprea Therapeutics Price Performance

The stock has a market cap of $8.75 million, a P/E ratio of -0.64 and a beta of 1.66. The stock has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.11. As a group, sell-side analysts forecast that Aprea Therapeutics, Inc. will post -0.34 earnings per share for the current year.

Institutional Trading of Aprea Therapeutics

An institutional investor recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC increased its holdings in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,015,541 shares of the company’s stock after buying an additional 645,000 shares during the period. AIGH Capital Management LLC owned about 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on restoring the function of mutated p53, a tumor-suppressor protein that is altered in many cancers and plays an important role in regulating cell growth and programmed cell death.

Aprea’s pipeline has included eprenetapopt (APR-246), an investigational therapy designed to reactivate mutant p53, as well as next-generation p53-reactivating compounds such as APR-548.